1. Abrams, D., Schulze-Neick, I., and Magee, A. G., Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.Heart, 84, E4 (2000).
2. Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. R., Bourge, R. C., Brundage, B. H., Koerner, S. K., Langleben, D., Keller, C. A., Murali, S., Uretsky, B. R., Clayton, L. M., Jobsis, M. M., Blackburn, S. D., Shortino, D., and Crow, J. W., A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.N. Engl. J. Med., 334, 296–302 (1996).
3. Braner, D. A., Rineman, J. R., Chang, R., and Soifer, S. J., M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs.Am. J. Physiol., 264, H252-H258 (1993).
4. Cassis, L. A., Rippetoe, P. E., Soltis, E. E., Painter, D. J., Pitz, R., and Gillespie, M. N., Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist.J. Pharmacol. Exp. Ther., 262, 1168–1172 (1992).
5. Chen, L., Gan, X. T., Haist, J. V., Peng, Q., Lu, X., Chakrabarti, S., and Karmazyn, M., Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the Na+-H+ exchange inhibitor cariporide.J. Pharmacol. Exp. Ther., 298, 469–476 (2001).